Pembrolizumab: tested in a combination

521 studies: another drug in the study is under test too. Page 5 of 6. Open to participants first (187), then studies with results posted, then the rest; newest registration first within each.

• A Study to Evaluate Pembrolizumab Plus Lenvatinib in PD-L1 Positive TKI Resistant NSCLC PatientsActive, not recruitingNCT05078931Phase 2Report a problem
• Pembrolizumab and Lenvatinib for the Treatment of Advanced, Unresectable, or Metastatic Gastroesophageal AdenocarcinomaActive, not recruitingNCT05041153Early Phase 1Report a problem
• Phase II Trial of Pembrolizumab Plus Lenvatinib in Advanced Adrenal Cortical CarcinomaActive, not recruitingNCT05036434Phase 2Report a problem
• PD-1 Inhibitor Combined With Bevacizumab and FOLFIRI Regimen in the Second-line Treatment of Advanced Colorectal CancerStatus unknownNCT05035381Phase 2Report a problem
• Comprehensive Analysis of Predictors of the Treatment With Pembrolizumab and Olaparib in Patients With Unresectable or Metastatic HER2 Negative Breast Cancer and a Deleterious Germline Mutation or a Homologous Recombination Deficiency (COMPRENDOActive, not recruitingNCT05033756Phase 2Report a problem
• Study of Pembrolizumab Combined With Anlotinib in the First Line Therapy for R/M HNSCC With CPS≥1Status unknownNCT04999800Phase 2Report a problem
• Chemotherapy Combined with ICIs in First-line Alectinib Failed Patients with ALK-rearranged NSCLCCompletedNCT04997382Phase 2Report a problem
• Pembrolizumab and Axitinib as Neoadjuvant Therapy for Locally Advanced Non-metastatic Clear Cell Renal Cell CarcinomaStatus unknownNCT04995016Phase 2Report a problem
• Pembrolizumab, Lenvatinib and Chemotherapy After TKIs in NSCLCStatus unknownNCT04989322Phase 2Report a problem
• Pembrolizumab in Combination With Gemcitabine in People With Advanced Mycosis Fungoides or Sézary SyndromeActive, not recruitingNCT04960618Phase 2Report a problem
• Study of a Pembrolizumab-based Organ Preservation Strategy for Locally Advanced Larynx CancersCompletedNCT04943445Phase 2Report a problem
• REduced Frequency ImmuNE Checkpoint Inhibition in CancersStatus unknownNCT04913025Phase 2Report a problem
• Lenvatinib and Pembrolizumab Maintenance Therapy for the Treatment of Patients of Advanced Unresectable Pancreatic CancerActive, not recruitingNCT04887805Phase 2Report a problem
• Trial Exploring Combined Neoadjuvant Therapy With Pembrolizumab/Lenvatinib + Adjuvant Pembrolizumab in Pat. With NSCLCActive, not recruitingNCT04875585Phase 2Report a problem
• First Line Weekly Chemo/Immunotherapy for Metastatic Head/Neck Squamous Cell Carcinoma PatientsActive, not recruitingNCT04858269Phase 2Report a problem
• Pembrolizumab and Olaparib in Recurrent/Metastatic, Platinum Resistant Nasopharyngeal CancerActive, not recruitingNCT04825990Phase 2Report a problem
• Safety and Oversight of the Individually Tailored Treatment Approach: A Novel Pilot StudyTerminatedNCT04801966Not applicableReport a problem
• Brentuximab Vedotin and Pembrolizumab in Treating Patients With Recurrent Peripheral T-Cell LymphomaWithdrawnNCT04795869Phase 2Report a problem
• Tucatinib Together With Pembrolizumab and TrastuzumabTerminatedNCT04789096Phase 2Report a problem
• Lenvatinib and Pembrolizumab in People With Advanced Soft Tissue SarcomaActive, not recruitingNCT04784247Phase 2Report a problem
• Regorafenib-pembrolizumab vs. TACE/TARE in Intermediate Stage HCC Beyond Up-to-7TerminatedNCT04777851Phase 3Report a problem
• Study of Pembrolizumab With Single Agent Chemotherapy in Elderly Patients With Advanced NSCLCWithdrawnNCT04754815Phase 2Report a problem
• An Open Label Phase 2 Study to Evaluate the Safety and Efficacy of Lenvatinib With Pembrolizumab or Lenvatinib, Pembrolizumab and FLOT in the Neoadjuvant / Adjuvant Treatment for Patients With Gastric CancerActive, not recruitingNCT04745988Phase 2Report a problem
• Metastatic Solid Cancer Clinical TrialCompletedNCT04739618Phase 2Report a problem
• Pembrolizumab and Lenvatinib/Chemotherapy for Poorly Differentiated/Anaplastic Thyroid CancerWithdrawnNCT04731740Phase 2Report a problem
• Pembrolizumab And Lenvatinib In Leptomeningeal MetastasesTerminatedNCT04729348Phase 2Report a problem
• A Phase 2 Trial for Patients With Metastatic Solid CancerActive, not recruitingNCT04713371Phase 2Report a problem
• Combination of Pembrolizumab and Lenvatinib, in Pre-treated Thymic CArcinoma paTIentsCompletedNCT04710628Phase 2Report a problem
• Sargramostim (GM-CSF) + PD-1WithdrawnNCT04703426Phase 2Report a problem
• Perioperative Enfortumab Vedotin (EV) Plus Pembrolizumab (MK-3475) Versus Neoadjuvant Chemotherapy for Cisplatin-Eligible Muscle Invasive Bladder Cancer (MIBC) (MK-3475-B15/ KEYNOTE-B15 / EV-304)Active, not recruitingNCT04700124Phase 3Report a problem
• Trial of Lenvatinib Plus PembrolizumAb in Recurrent Gynecological Clear Cell Adenocarcinomas (LARA)Status unknownNCT04699071Phase 2Report a problem
• Pembrolizumab, Dabrafenib, and Trametinib Before Surgery for the Treatment of BRAF-Mutated Anaplastic Thyroid CancerActive, not recruitingNCT04675710Phase 2Report a problem
• The Combination of Anlotinib and Immune Checkpoint Inhibitors for Advanced NSCLC Patients With Muti-line TherapyCompletedNCT04670107Phase 1/2Report a problem
• A Study of Pembrolizumab and Olaparib for People With Metastatic Pancreatic Ductal Adenocarcinoma and Homologous Recombination Deficiency or Exceptional Treatment Response to Platinum-Based TherapyActive, not recruitingNCT04666740Phase 2Report a problem
• Pembrolizumab Plus Olaparib in Patients With Recurrent Cervical CancerStatus unknownNCT04641728Phase 2Report a problem
• Phase II Study of Olaparib and Pembrolizumab in Advanced Melanoma With Homologous Recombination (HR) MutationStatus unknownNCT04633902Phase 2Report a problem
• Placebo-controlled, Study of Concurrent Chemoradiation Therapy With Pembrolizumab Followed by Pembrolizumab and Olaparib in Newly Diagnosed Treatment-Naïve Limited-Stage Small Cell Lung Cancer (LS-SCLC) (MK 7339-013/KEYLYNK-013)Active, not recruitingNCT04624204Phase 3Report a problem
• Lenvatinib and Pembrolizumab in Resectable Mucosal MelanomaStatus unknownNCT04622566Phase 2Report a problem
• Brentuximab Vedotin With Pembrolizumab in Metastatic Solid TumorsCompletedNCT04609566Phase 2Report a problem
• Chemotherapy Combined With Pembrolizumab in Treating Patients With Thymoma and Thymic CarcinomaStatus unknownNCT04554524Phase 4Report a problem
• Pembrolizumab in Combination With Lenvatinib in Patients With Advanced Biliary Tract CarcinomaCompletedNCT04550624Phase 2Report a problem
• Phase 0 Master Protocol for CIVO Intratumoral Microdosing of Anti-Cancer TherapiesActive, not recruitingNCT04541108Early Phase 1Report a problem
• TOPAZ: Tucatinib in COmbination With Pembrolizumab And TrastuZumab in Patients With HER2-Positive Breast Cancer Brain MetastasesWithdrawnNCT04512261Phase 1/2Report a problem
• Using Biomarkers to Help Guide Safe Immunotherapy Discontinuation in Patients With Unresectable Stage IIIB-IV Melanoma, The PET-Stop TrialActive, not recruitingNCT04462406Phase 2Report a problem
• Preoperative Lenvatinib Plus Pembrolizumab in Early-Stage Triple-Negative Breast Cancer (TNBC)Active, not recruitingNCT04427293Phase 1Report a problem
• Pembrolizumab and LENvatinib in Participants With Hepatocellular Carcinoma (HCC) Before Liver TransplantStatus unknownNCT04425226Not applicableReport a problem
• Olaparib Monotherapy and Olaparib + Pembrolizumab Combination Therapy for Ovarian CancerCompletedNCT04417192Phase 2Report a problem
• Pembrolizumab Plus Pemetrexed for Elderly Patients With Non-Sq NSCLC With PD-L1 < 50%: CJLSG1901Status unknownNCT04396457Phase 2Report a problem
• A Study With Pembrolizumab for Non-small Cell Lung Cancer (NSCLC)Status unknownNCT04393883Not applicableReport a problem
• Study of Pembrolizumab With Concurrent Chemoradiation Therapy Followed by Pembrolizumab With or Without Olaparib in Stage III Non-Small Cell Lung Cancer (NSCLC) (MK-7339-012/KEYLYNK-012)Active, not recruitingNCT04380636Phase 3Report a problem
• "QUAD SHOT" Radiotherapy With Pembrolizumab in Patients With Recurrent Head & Neck CancerActive, not recruitingNCT04373642Phase 2Report a problem
• Olaparib Maintenance With Pembrolizumab & Bevacizumab in BRCA Non-mutated Patients With Platinum-sensitive Recurrent Ovarian CancerStatus unknownNCT04361370Phase 2Report a problem
• Efficacy of Immunotherapy Plus a Drug in Patients With Progressive Advanced Mucosal Cancer of Different LocationsCompletedNCT04357873Phase 2Report a problem
• Checkpoint Blockade in COVID-19 PandemicTerminatedNCT04335305Phase 2Report a problem
• Pembrolizumab Plus Lenvatinib In Second Line and Third Line Malignant Pleural mesotheLioma PatientsActive, not recruitingNCT04287829Phase 2Report a problem
• The CAPER Trial: A Phase Ib Clinical Trial of Cyclophosphamide And PEmbrolizumab in Metastatic Renal Cell CarcinomaStatus unknownNCT04262427Phase 1/2Report a problem
• Cabozantinib Plus Pembrolizumab for Recurrent, Persistent and/or Metastatic Cervical CancerTerminatedNCT04230954Phase 2Report a problem
• Lenvatinib and Pembrolizumab in People With Advanced Adenoid Cystic Carcinoma and Other Salivary Gland CancersActive, not recruitingNCT04209660Phase 2Report a problem
• A Phase II Study of Neoadjuvant Pembrolizumab & Lenvatinib for Resectable Stage III MelanomaActive, not recruitingNCT04207086Phase 2Report a problem
• Study of Pembrolizumab and Ramucirumab in Pts With Progressive TCC After Treatment With an Immune Checkpoint InhibitorWithdrawnNCT04179110Phase 2Report a problem
• Lenvatinib and Pembrolizumab for the Treatment of Stage IVB Locally Advanced and Unresectable or Stage IVC Metastatic Anaplastic Thyroid CancerActive, not recruitingNCT04171622Phase 2Report a problem
• Efficacy and Safety Study of Anlotinib With Pembrolizumab in Adults With Programmed Cell Death-Ligand 1 (PD-L1)-Positive Treatment-naïve Non-small Cell Lung CancerStatus unknownNCT04164745Phase 2Report a problem
• Evaluating Length of Treatment With PD-1/PD-L1 Inhibitor in Advanced Solid TumorsCompletedNCT04157985Phase 3Report a problem
• Pembrolizumab + Platinum Doublets Without Radiation for Programmed Death-ligand 1 (PD-L1) ≥50% Locally Advanced NSCLCStatus unknownNCT04153734Phase 2Report a problem
• Study of PD-1 Inhibitors After CD30.CAR T Cell Therapy in Relapsed/Refractory Hodgkin LymphomaActive, not recruitingNCT04134325Early Phase 1Report a problem
• Study of Olaparib (MK-7339) in Combination With Pembrolizumab (MK-3475) in the Treatment of Homologous Recombination Repair Mutation (HRRm) and/or Homologous Recombination Deficiency (HRD)-Positive Advanced Cancer (MK-7339-007/KEYLYNK-007)CompletedNCT04123366Phase 2Report a problem
• Pembrolizumab Administered Via the Sofusa® DoseConnect™ in Patients With Relapsed/Refractory Cutaneous T-cell Lymphoma.Status unknownNCT04118868Phase 1Report a problem
• Abemaciclib + Pembrolizumab In GlioblastomaWithdrawnNCT04118036Phase 2Report a problem
• Novel SEQUEnced Immunotherapy With Anti-angiogenesis and Chemotherapy in Advanced gastroesophageaL AdenocarcinomaActive, not recruitingNCT04069273Phase 2Report a problem
• Neoadjuvant Therapy of Pembrolizumab + Ramucirumab for PD-L1 Positive Stage IB-IIIA Lung Cancer (EAST ENERGY)Active, not recruitingNCT04040361Phase 2Report a problem
• Dual PD-1 and JAK2 Inhibition in Hematological MalignanciesWithdrawnNCT04016116Phase 2Report a problem
• Pembrolizumab With Ataluren in Patients With Metastatic pMMR and dMMR Colorectal Carcinoma or Metastatic dMMR Endometrial Carcinoma: the ATAPEMBRO StudyStatus unknownNCT04014530Phase 1/2Report a problem
• Window of Opportunity Study in Colorectal CancerCompletedNCT03984578Phase 2Report a problem
• Epicutaneous Cryoimmunotherapy Combined With Pembrolizumab for Cutaneous Metastatic Breast CancerTerminatedNCT03982004Phase 1Report a problem
• Clinical Study on the Second-line and Above Treatment of Advanced Solid Tumor With Anlotinib Combined With Pd-1 AntibodyStatus unknownNCT03975036Phase 2/3Report a problem
• Androgen Deprivation Therapy (ADT) and Pembrolizumab for Advanced Stage Androgen Receptor-positive Salivary Gland CarcinomaActive, not recruitingNCT03942653Phase 2Report a problem
• Lenvatinib Combined Pembrolizumab in Advanced Hepatobiliary TumorsCompletedNCT03895970Phase 2Report a problem
• Gut Microbiome Modulation to Enable Efficacy of Checkpoint-based Immunotherapy in Pancreatic AdenocarcinomaWithdrawnNCT03891979Phase 4Report a problem
• Pembrolizumab And Tamoxifen Among Women With Advanced Hormone Receptor Positive Breast Cancer And Esr1 MutationStatus unknownNCT03879174Phase 2Report a problem
• Testing the Timing of Pembrolizumab Alone or With Chemotherapy as First Line Treatment and Maintenance in Non-small Cell Lung CancerActive, not recruitingNCT03793179Phase 3Report a problem
• Neoadjuvant Pembrolizumab Plus Androgen Axis Blockade Prior to Prostatectomy for High Risk Localized Prostate CancerStatus unknownNCT03753243Phase 2Report a problem
• ICIs Neoadjuvant Therapy in Resectable Non-Small-Cell Lung CancerCompletedNCT03732664Phase 1Report a problem
• SBRT and Anti-programmed Cell Death Protein 1(Anti-PD-1) in Late Stage or Recurrent Pancreatic Cancer PatientsTerminatedNCT03716596Phase 1Report a problem
• Afatinib and Pembrolizumab for Head and Neck Squamous Cell Carcinoma (ALPHA Study)CompletedNCT03695510Phase 2Report a problem
• Immunotherapy +/- EGFR Inhibitor In Advanced/Metastatic cSCC: Tackling Primary And Secondary ResistanceStatus unknownNCT03666325Phase 2Report a problem
• Study of Pembrolizumab With Pemetrexed and Oxaliplatin in Chemo-Refractory Metastatic Colorectal Cancer PatientsStatus unknownNCT03626922Phase 1Report a problem
• Pembro + Blina Combination in Pediatric and Young Adult Patients With Relapsed/Refractory Acute Leukemia or LymphomaWithdrawnNCT03605589Phase 1Report a problem
• Pembrolizumab in Combination with Bevacizumab and Pegylated Liposomal Doxorubicin in Patients with Ovarian CancerCompletedNCT03596281Phase 1Report a problem
• Phase 1b Study of Pegylated Liposomal Doxorubicin and Pembrolizumab in Endocrine-resistant Breast CancerStatus unknownNCT03591276Phase 1/2Report a problem
• Peri-Operative Immune Checkpoint Inhibition and Cryoablation in Women With Triple-negative Breast CancerActive, not recruitingNCT03546686Phase 2Report a problem
• Pembrolizumab and Blinatumomab in Treating Participants With Recurrent or Refractory Acute Lymphoblastic LeukemiaActive, not recruitingNCT03512405Phase 1/2Report a problem
• Pembrolizumab and Paclitaxel in Hypermutated Breast CancerCompletedNCT03492918Phase 2Report a problem
• Perioperative mFOLFOX Plus Pembrolizumab in Gastroesophageal Junction (GEJ) and Stomach AdenocarcinomaActive, not recruitingNCT03488667Phase 2Report a problem
• Pembrolizumab and Nab Paclitaxel in Patients With Metastatic Urothelial CarcinomaCompletedNCT03464734Phase 2Report a problem
• Pembrolizumab and Sunitinib Malate in Treating Participants With Refractory Metastatic or Unresectable Thymic CancerActive, not recruitingNCT03463460Phase 2Report a problem
• Pembrolizumab in Combination With Decitabine and Hypofractionated Index Lesion Radiation in Pediatrics and Young AdultsCompletedNCT03445858Early Phase 1Report a problem
• Study of Pembrolizumab Plus Fulvestrant in Hormone Receptor Positive, HER-2 Negative Advanced/Metastatic Breast Cancer PatientsActive, not recruitingNCT03393845Phase 2Report a problem
• Pembrolizumab With Chemotherapy for Poorly Chemo-responsive Thyroid and Salivary Gland TumorsActive, not recruitingNCT03360890Phase 2Report a problem
• Neoadjuvant Treatment Associated With Maintenance Therapy by Anti-PD1 Immunotherapy in Patients With Resectable Head and Neck Mucosal MelanomaActive, not recruitingNCT03313206Phase 2Report a problem
• Denosumab and Pembrolizumab in Clear Cell Renal CarcinomaStatus unknownNCT03280667Phase 2Report a problem

← Pembrolizumab